Literature DB >> 25608151

Hybrid imaging for pancreatic malignancy: clinical applications, merits, limitations, and pitfalls.

Priyanka Jha1, Bijan Bijan, Giselle Melendres, David K Shelton.   

Abstract

The role of PET/CT in pancreatic malignancy is evolving with new scientific evidence emerging continuously. PET/CT applications in imaging the pancreas and its organ-specific merits, limitations, and potential pitfalls are still evolving. This article provides an overview of the state-of-the-art applications of PET/CT imaging in evaluating pancreatic malignancy, comparing with conventional imaging modalities, such as contrast-enhanced CT and MRI. Current PET/MRI is also reviewed, along with brief discussion on cost-benefit analysis.

Entities:  

Mesh:

Year:  2015        PMID: 25608151     DOI: 10.1097/RLU.0000000000000677

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study.

Authors:  Felipe S Furtado; Cristina R Ferrone; Susanna I Lee; Mark Vangel; David A Rosman; Colin Weekes; Motaz Qadan; Carlos Fernandez-Del Castillo; David P Ryan; Lawrence S Blaszkowsky; Theodore S Hong; Jeffrey W Clark; Robin Striar; David Groshar; Lina G Cañamaque; Lale Umutlu; Onofrio A Catalano
Journal:  Mol Imaging Biol       Date:  2021-01-07       Impact factor: 3.488

2.  Pretherapeutic Assessment of Pancreatic Cancer: Comparison of FDG PET/CT Plus Delayed PET/MR and Contrast-Enhanced CT/MR.

Authors:  Zaizhu Zhang; Nina Zhou; Xiaoyi Guo; Nan Li; Hua Zhu; Zhi Yang
Journal:  Front Oncol       Date:  2022-01-14       Impact factor: 6.244

Review 3.  Clinical Utility of Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI) in Gastrointestinal Cancers.

Authors:  Robert Matthews; Minsig Choi
Journal:  Diagnostics (Basel)       Date:  2016-09-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.